Schedule 13G ownership disclosure

Viridian Therapeutics Inc

Common Stock, $0.01 par value per share · CUSIP: 92790C104

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Venrock Healthcare Capital Partners III, L.P.

    Shares: 3,575,309.00 · Class: 4.5%

  • VHCP Co-Investment Holdings III, LLC

    Shares: 3,575,309.00 · Class: 4.5%

  • Venrock Healthcare Capital Partners EG, L.P.

    Shares: 3,575,309.00 · Class: 4.5%

  • VHCP Management III, LLC

    Shares: 3,575,309.00 · Class: 4.5%

  • VHCP Management EG, LLC

    Shares: 3,575,309.00 · Class: 4.5%

  • Nimish Shah

    Shares: 3,575,309.00 · Class: 4.5%

  • Bong Y Koh

    Shares: 3,575,309.00 · Class: 4.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-25-004228
Form type
SCHEDULE 13G/A
Filer
Venrock Healthcare Capital Partners III, L.P.
CIK
CIK 1738048
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub